$ELOX Cashflow Statement | Understand Stock

$ELOX

$13.34 +$0.17 (1.29%) Close

$ELOX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Stock-based compensation
Depreciation
Impairment of property and equipment
Amortization of operating lease right-of-use asset
Amortization of debt discount
Amortization, net, of premiums and discounts on investments
Increase in fair value of derivative liabilities
Gain on extinguishment of PPP debt
Imputed interest expense on 2025 bridge loans
Change in fair value of warrant liabilities
Extinguishment of the 2021 Award
Write-off of fair value of derivative liabilities
Loss on extinguishment of debt
Loss on issuance of common stock
Gain on debt conversion
Gain on sales and disposals of property and equipment
Changes in operating assets and liabilities:
License and service receivable
Unbilled receivable
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Merger related costs paid
Accrued interest
Operating lease liabilities
Taxes payable

Net cash used in operating activities
Cash flows from investing activities:
Cash acquired in merger activities
Purchases of marketable securities
Proceeds from maturities of marketable securities
Purchase of property and equipment
Proceeds from sales of property and equipment
Cash paid for long-term deposits
Cash received (paid) for long-term deposits
Proceeds from Sale of Other Property, Plant, and Equipment
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from the issuance of common stock, pre-funded warrants, and common stock warrants, net of issuance costs
Proceeds from the sale of common stock through ATM program, net of issuance costs
Equity Sales Agreement
Underwritten Public Offering
Total proceeds from the sale of common stock through ATM program, net of issuance costs

Proceeds from issuance of pre-funded warrants in connection with the 2025 PIPE transaction, net issuance costs
Proceeds from debt financing obligation
Payment of debt issuance costs
Repayment of term loan principal
Proceeds from exercises of stock options
Payment for settlement of taxes upon vesting of restricted stock units
Proceeds (repayment) from advances from collaboration partners
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of the year
Cash, cash equivalents and restricted cash at the end of the year
Supplemental disclosure of cash flow activities:
Cash paid for interest
Cash paid for income taxes, net of refunds received

Noncash financing activities:
Non-cash issuance of common stock upon exercise of warrants
Right-of-use assets obtained in exchange for lease liabilities
Fair value of common stock and pre-funded warrants issued to loan holder
Domicilium debt conversion, (principal of $7,366 and accrued interest of $1,131)
Fair value of warrants issued in connection with long-term debt
Remeasurement of operating leases

Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheet:
Cash and cash equivalents
Restricted cash

Comments